CONy 2021 | The future of Parkinson’s disease treatments
Lars Wojtecki, MD, PhD, Institute of Clinical Neuroscience and Medical Psychology, University Düsseldorf, Düsseldorf, Germany, shares his perspectives on the future of treatment landscape of Parkinson’s disease. Prof. Wojtecki believes that the upcoming treatments, some already in development, will target beyond the dopaminergic pathway. Regarding deep brain stimulation, past learnings will improve its use in the future. However, the biggest challenge going forward is interfering with the cause of Parkinson’s disease. Therefore, it is essential to develop treatments that are not only symptomatic but target the underlying cause. This interview was conducted during the virtual 2021 World Congress on Controversies in Neurology (CONy).
Disclosures
Grants/Institutional Support: Hilde Ulrichs Stiftung für Parkinsonforschung, ParkinsonFonds Deutschland, BMBF/ERA-NETNEURON, DFG Forschergruppe (FOR1328), Deutsche Parkinson Vereinigung (DPV), Forschungskommission, Medizinische Fakultät, HHU Düsseldorf, UCB; Medtronic, UCB, Teva, Allergan, Merz,Abbvie, Roche, Bial, Merck, Novartis, Desitin, Spectrum
Honorary/Travel Grants/Consultancy: TEVA, UCB Schwarz, Desitin, Medtronic, Abbott/Abbvie, MEDA, Boehringer I, Storz Medical, Kyowa Kirin, Guidepoint, Merck, Merz, Synergia, BIAL, Zambon, Sapio Life, STADA, Inomed.
Stock Ownership : BionTech
